Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.

Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Int Urol Nephrol. 2019 Sep 21. doi: 10.1007/s11255-019-02284-1. [Epub ahead of print]

PMID:
31542882
2.

Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.

Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

World J Urol. 2018 Sep;36(9):1399-1407. doi: 10.1007/s00345-018-2310-y. Epub 2018 May 2.

PMID:
29717358
3.

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.

Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Eur Urol Oncol. 2018 Aug;1(3):215-222. doi: 10.1016/j.euo.2018.03.007. Epub 2018 May 15.

PMID:
31102624
4.

Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.

Leyh-Bannurah SR, Karakiewicz PI, Pompe RS, Preisser F, Zaffuto E, Dell'Oglio P, Briganti A, Nafez O, Fisch M, Steuber T, Graefen M, Budäus L.

World J Urol. 2019 Mar;37(3):469-479. doi: 10.1007/s00345-018-2396-2. Epub 2018 Jul 10.

PMID:
29992380
5.

Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study.

Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, Shariat SF, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Urol Oncol. 2019 Oct;37(10):702-710. doi: 10.1016/j.urolonc.2019.04.023. Epub 2019 May 15.

PMID:
31103337
6.

Local Therapy Improves Survival in Metastatic Prostate Cancer.

Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI.

Eur Urol. 2017 Jul;72(1):118-124. doi: 10.1016/j.eururo.2017.03.020. Epub 2017 Apr 3.

PMID:
28385454
7.

Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.

Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, Shariat SF, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Prostate. 2018 May;78(6):469-475. doi: 10.1002/pros.23491. Epub 2018 Feb 19.

PMID:
29460290
8.

Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.

Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, Shariat SF, Briganti A, Saad F, Karakiewicz PI.

World J Urol. 2018 Jan;36(1):7-13. doi: 10.1007/s00345-017-2102-9. Epub 2017 Oct 23.

PMID:
29063268
9.
10.

Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.

Smith GD, Pickles T, Crook J, Martin AG, Vigneault E, Cury FL, Morris J, Catton C, Lukka H, Warner A, Yang Y, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):505-16. doi: 10.1016/j.ijrobp.2014.11.018. Epub 2015 Jan 13.

PMID:
25596107
11.

Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in D'Amico Intermediate- and High- Risk Radical Prostatectomy Patients: A Multi-Institutional Study.

Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, Taille A, Briganti A, Salomon L, Ploussard G, Tilki D; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).

J Urol. 2019 Aug 22:101097JU0000000000000504. doi: 10.1097/JU.0000000000000504. [Epub ahead of print]

PMID:
31437119
12.

Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database.

Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, Shariat SF, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2018 May 22. pii: S2405-4569(18)30123-8. doi: 10.1016/j.euf.2018.05.006. [Epub ahead of print]

PMID:
29802052
13.

Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.

Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):904-911. doi: 10.1016/j.ijrobp.2017.07.034. Epub 2017 Jul 31.

PMID:
29063853
14.

External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.

Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, Soria F, Mattei A, Montorsi F, Briganti A, Shariat SF.

Eur Urol. 2019 Feb;75(2):319-328. doi: 10.1016/j.eururo.2018.09.034. Epub 2018 Oct 4.

PMID:
30293908
15.

External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.

Wang C, Kishan AU, Kamrava M, Steinberg ML, King CR.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1045-1052. doi: 10.1016/j.ijrobp.2017.03.040. Epub 2017 Mar 31.

PMID:
28721887
16.

Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.

Sheng W, Kirschner-Hermanns R, Zhang H.

World J Urol. 2019 Feb;37(2):317-325. doi: 10.1007/s00345-018-2389-1. Epub 2018 Jun 27.

PMID:
29951790
17.

Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy.

Schiffmann J, Lesmana H, Tennstedt P, Beyer B, Boehm K, Platz V, Tilki D, Salomon G, Petersen C, Krüll A, Graefen M, Schwarz R.

Strahlenther Onkol. 2015 Apr;191(4):330-7. doi: 10.1007/s00066-014-0794-y. Epub 2014 Dec 4.

PMID:
25471276
18.

Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W.

Radiother Oncol. 2019 Mar;132:211-217. doi: 10.1016/j.radonc.2018.10.013. Epub 2018 Oct 30.

PMID:
30389241
19.

A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.

Leyh-Bannurah SR, Dell'Oglio P, Tian Z, Schiffmann J, Shariat SF, Suardi N, Francesco M, Alberto B, Heinzer H, Huland H, Graefen M, Budäus L, Karakiewicz PI.

World J Urol. 2017 Feb;35(2):189-197. doi: 10.1007/s00345-016-1863-x. Epub 2016 Jun 11.

PMID:
27289238
20.

Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study.

Gu X, Gao X, Cui M, Xie M, Ma M, Qin S, Li X, Qi X, Bai Y, Wang D.

Cancer Manag Res. 2018 May 8;10:1061-1067. doi: 10.2147/CMAR.S157442. eCollection 2018.

Supplemental Content

Support Center